Cellen Announced as a Finalist for Life Sciences Award




One Nucleus has revealed the finalists of its annual BioNewsRound Award, recognising life science companies who have announced exciting developments for patients and the wider sector. Cellen has been announced as one of 6 leading life science organisations shortlisted for the 2020 award.


Companies and research organisations were nominated for their most important news stories from the last year. These were assessed based on their impact on the organisation, whether they demonstrated an exciting development in the life sciences sector or whether they have the potential to significantly benefit patients.


We are delighted that Cellen was listed as a finalist, alongside 5 other organisations:

  • Abcam IPO - Abcam Announces Pricing of Offering on NASDAQ

  • Catalent – Catalent Completes Acquisition of MaSTherCell

  • Cellen - Online Clinic Launched for Patients Living with Persistent Pain

  • Oxeia - Announces Initiation of Phase 2 Trial for OXE103

  • Salvia BioElectronics – Salvia BioElectronics Receives FDA Breakthrough Device Designation for Innovative Neurostimulation Solution

  • Storm Therapeutics – Storm Therapeutics Selects First-in-Class Clinical Candidate Targeting METTL3

The winner will be announced at the culmination of the prestigious annual Genesis conference, held virtually this year on 10th December. Now in its 20th year, Genesis 2020 will assemble senior executives and decision-makers from across the Life Science, Healthcare and Technology field to present, discuss and demonstrate their collective insight and thought leadership for the sector, themselves and their stakeholders.


We look forward to Genesis 2020, and are thrilled to be recognised as a leader in the life sciences and pain management sector.


To find out more, please contact us at contact@cellenhealth.com